Prospektywne, wieloośrodkowe, nieinterwencyjne badanie mające na celu zbadanie skuteczności REKOVELLE® w stymulacji jajników u azjatyckich kobiet w rzeczywistych warunkach (PROFOUND)
Prospektywne, nieinterwencyjne badanie obejmujące wiele krajów, mające na celu zbadanie leku REKOVELLE w stymulacji jajników: skuteczność, bezpieczeństwo i wzorce stosowania u azjatyckich kobiet w rzeczywistej praktyce
Primary objective is to investigate the effectiveness of REKOVELLE® in women undergoing their first REKOVELLE® ovarian stimulation treatment in real world practice in Asian countries.
Przegląd badań
Status
Status
Warunki
Warunki
Interwencja / Leczenie
Interwencja / Leczenie
Typ studiów
Typ studiów
Zapisy (Rzeczywisty)
Zapisy
Kontakty i lokalizacje
Lokalizacje studiów
-
-
-
Hiroshima, Japonia, 7300035
- Ferring Investigational Site
-
Hokkaido, Japonia, 0600003
- Ferring Investigational Site
-
Hyōgo, Japonia, 6500021
- Ferring Investigational Site
-
Osaka, Japonia, 5300011
- Ferring Investigational Site
-
Osaka, Japonia, 5500015
- Ferring Investigational Site
-
Saitama, Japonia, 3540035
- Ferring Investigational Site
-
-
Chiba
-
Chiba, Chiba, Japonia, 2610023
- Ferring Investigational Site
-
-
Fukuoka
-
Fukuoka, Fukuoka, Japonia, 8120013
- Ferring Investigational Site
-
Kitakyushu, Fukuoka, Japonia, 8070825
- Ferring Investigational Site
-
-
Gunma
-
Takasaki, Gunma, Japonia, 3700841
- Ferring Investigational Site
-
-
Hiroshima
-
Hiroshima, Hiroshima, Japonia, 7320822
- Ferring Investigational Site
-
-
Japan
-
Bunkyō City, Japan, Japonia, 1130033
- Ferring Investigational Site
-
-
Tokyo
-
Tokyo, Tokyo, Japonia, 1600023
- Ferring Investigational Site
-
-
-
-
-
Busan, Korea Południowa, 47245
- Ferring Investigational Site
-
Seoul, Korea Południowa, 02586
- Maria Fertility Hospital
-
-
Busan
-
Busan, Busan, Korea Południowa, 49241
- Ferring Investigational Site
-
-
Daegu
-
Daegu, Daegu, Korea Południowa, 41910
- Ferring Investigational Site
-
-
Seongnam
-
Seongnam-si, Seongnam, Korea Południowa, 13496
- Ferring Investigational Site
-
-
-
-
-
Bangkok, Tajlandia, 10700
- Ferring Investigational Site
-
-
Muang
-
Phitsanulok, Muang, Tajlandia, 65000
- Naresuan University Hospital
-
-
Ratchathewi
-
Bangkok, Ratchathewi, Tajlandia, 10400
- Ramathibodi Hospital
-
-
-
-
-
Taichung, Tajwan, 406
- Ferring Investigational Site
-
Taipei, Tajwan, 100225
- Ferring Investigational Site
-
Taipei, Tajwan, 110
- Ferring Investigational Site
-
-
Tainan
-
Tainan, Tainan, Tajwan, 70403
- Ferring Investigational Site
-
Tainan, Tainan, Tajwan, 71004
- Ferring Investigational Site
-
-
Taoyuan
-
Taoyuan, Taoyuan, Tajwan, 333
- Ferring Investigational Site
-
-
-
-
Hanoi
-
Hanoi, Hanoi, Wietnam, 100000
- Ferring Investigational Site
-
-
Ho Chi Minh City
-
Ho Chi Minh City, Ho Chi Minh City, Wietnam, 700000
- Ferring Investigational Site
-
Ho Chi Minh City, Ho Chi Minh City, Wietnam
- Ferring Investigational Site
-
-
Huế
-
Huế, Huế, Wietnam, 49000
- Ferring Investigational Site
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Kryteria kwalifikacji
Wiek uprawniający do nauki
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Metoda próbkowania
Badana populacja
Approximately 1500 patients prescribed REKOVELLE for the first time for controlled overian stimulation (COS) will be enrolled in the study.
Opis
Inclusion Criteria:
- Females aged 20 years or older at enrollment
- Serum AMH level >0.5 ng / mL (with the latest result tested within 12 months)
- Who are first time prescribed REKOVELLE for their ovarian stimulation and IVF or ICSI treatment cycle using fresh or frozen ejaculated sperm from male partner or sperm donor (if applicable)
- Willing and able to provide written informed consent
Exclusion Criteria:
- Have undergone more than 2 COS-IVF / ICSI cycles before the enrollment
- Participating in an interventional clinical trial in which any medication treatment is mandated
- Women with a contraindication for prescription of REKOVELLE treatment
- Oocyte donors
- Undergoing ovarian stimulation for fertility preservation
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Modele obserwacyjne: COHORT
- Perspektywy czasowe: PROSPECTIVE
Liczba grup / kohort
Kohorty i interwencje
Grupa / KohortaGrupa / Kohorta |
Interwencja / LeczenieInterwencja / Leczenie |
|---|---|
|
REKOVELLE
Participants prescribed REKOVELLE for the first time for controlled ovarian stimulation. |
Individualised dosing regiment of REKOVELLE in routine clinical practice. |
Co mierzy badanie?
Podstawowe miary wyniku
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Cumulative live birth rate
Ramy czasowe: Up to 12 months
|
Cumulative live birth rate defined as delivery of at least 1 live fetus after 20 completed weeks of gestation, combined fresh and frozen embryo transfers within 12 months after the start of the ovarian stimulation in patients of the first REKOVELLE ovarian stimulation cycle. |
Up to 12 months
|
Miary wyników drugorzędnych
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
The Luteinising hormone (LH) surge suppression protocol
Ramy czasowe: Up to 22 days
|
Treatment pattern will be measured by analysing the Lutenising hormone (LH) surge suppression protocol. |
Up to 22 days
|
|
Daily Dosage
Ramy czasowe: Up to 22 days
|
Treatment pattern will be measured by analysing the REKOVELLE and concomitant ovarian stimulation protocols, consisting of daily dosage. |
Up to 22 days
|
|
Stimulation Duration
Ramy czasowe: Up to 22 days
|
Treatment pattern will be measured by analysing the REKOVELLE and concomitant ovarian stimulation protocols, consisting of stimulation duration. |
Up to 22 days
|
|
Total Dosage
Ramy czasowe: Up to 22 days
|
Treatment pattern will be measured by analysing the REKOVELLE and concomitant ovarian stimulation protocols, consisting of total dosage. |
Up to 22 days
|
|
Trigger Protocol
Ramy czasowe: Up to 22 days
|
Treatment pattern will be measured by analysing the trigger protocol. |
Up to 22 days
|
|
Luteal phase support protocol
Ramy czasowe: Up to 22 days
|
Treatment pattern will be measured by analysing the luteal phase support protocol. |
Up to 22 days
|
|
Number of oocytes retrieved
Ramy czasowe: Up to 22 days
|
Number of oocytes retrieved at oocyte retrieval |
Up to 22 days
|
|
Number of Metaphase II (MII) oocytes
Ramy czasowe: Up to 22 days
|
Number of MII oocytes at oocyte retrieval (only applicable for Intracytoplasmic sperm injection (ICSI)) |
Up to 22 days
|
|
Number of embryos
Ramy czasowe: Day 3 after oocyte retrieval
|
Number of embryos on Day 3 after oocyte retrieved |
Day 3 after oocyte retrieval
|
|
Number of Blastocysts
Ramy czasowe: Day 5 after oocyte retrieval
|
Number of Blastocysts on Day 5 after oocyte retrieved |
Day 5 after oocyte retrieval
|
|
Number of embryos transferred
Ramy czasowe: Up to 28 days
|
Embryos transferred in fresh and/or frozen transfer cycles |
Up to 28 days
|
|
Number of blastocysts transferred
Ramy czasowe: Up to 28 days
|
Blastocysts transferred in fresh and/or frozen transfer cycles |
Up to 28 days
|
|
Implantation rate
Ramy czasowe: Up to 28 days
|
Number of gestational sacs, embryos or blastocysts transferred |
Up to 28 days
|
|
Positive human chorionic gonadotropin (hCG) rate
Ramy czasowe: 11 to 15 days after transfer
|
Positive human chorionic gonadotropin (hCG) rate analysed using serum or urine hCG test 11-15 days after transfer |
11 to 15 days after transfer
|
|
Clinical Pregnancy rate
Ramy czasowe: 4 to 5 weeks after transfer
|
Clinical pregnancy rate (at least 1 gestational sac 4-5 weeks after transfer) |
4 to 5 weeks after transfer
|
|
Vital Pregnancy
Ramy czasowe: 4 to 5 weeks after transfer
|
Vital pregnancy rate (at least 1 intrauterine gestational sac with fetal heartbeat 4-5 weeks after transfer) |
4 to 5 weeks after transfer
|
|
Ongoing pregnancy rate
Ramy czasowe: 9 to 11 weeks after transfer
|
Ongoing pregnancy rate (at least 1 intrauterine viable fetus 9-11 weeks after transfer) |
9 to 11 weeks after transfer
|
|
Time to pregnancy
Ramy czasowe: 4 to 5 weeks after transfer
|
Time to pregnancy from start date of ovarian stimulation to confirmation of clinical pregnancy |
4 to 5 weeks after transfer
|
|
Live birth rate
Ramy czasowe: More than 20 weeks after transfer
|
Live birth is defined as delivery of at least 1 live fetus after 20 completed weeks of gestation within 12 months after the start of the ovarian stimulation in patients of the first REKOVELLE ovarian stimulation cycle. |
More than 20 weeks after transfer
|
|
Multiple pregnancy rate
Ramy czasowe: 4 to 5 weeks after transfer
|
More than 1 gestational sac with fetal heart beat 4-5 weeks after transfer |
4 to 5 weeks after transfer
|
|
Spontaneous abortion rate
Ramy czasowe: Up to 10-11 weeks after transfer
|
Spontaneous abortion is defined as positive hCG test but all intrauterine gestational sacs without fetal heart beat as documented by ultrasound, or there are no viable fetuses observed by ultrasound |
Up to 10-11 weeks after transfer
|
|
Ectopic pregnancy rate
Ramy czasowe: Up to 10-11 weeks after transfer
|
Ectopic pregnancy is defined as extrauterine gestational sac with or without fetal heart beat as documented by ultrasound or surgery. |
Up to 10-11 weeks after transfer
|
|
Estradiol Hormone levels
Ramy czasowe: Up to 20 days
|
Estradiol hormone levels before stimulation and at the end of stimulation day |
Up to 20 days
|
|
Progesterone Hormone levels
Ramy czasowe: Up to 20 days
|
Progesterone hormone levels before stimulation and at the end of stimulation day |
Up to 20 days
|
|
Cycle cancellation rate and the reason for cycle cancellation
Ramy czasowe: Up to 28 days
|
Date when the investigator decides to cancel cycle before oocyte pick up (due to poor ovarian response, excessive ovarian response, any illness which prevents oocyte collection procedure, subject not taking hCG injection at the correct time, subject choice, other) or after oocyte pick-up (due to no oocytes collected, no oocytes fertilized, abnormal fertilization, abnormal embryo development, no embryo development, ovarian hyperstimulation syndrome (OHSS), subject choice, any other specified reason) |
Up to 28 days
|
|
Transfer cancellation rate and the reason for transfer cancellation
Ramy czasowe: Up to 28 days
|
Transfer cancellation rate and the reason for transfer cancellation (no embryo available for transfer, risk of OHSS, endometrium not receptive, high progesterone level, adverse event, any other specified reason for transfer cancellation). |
Up to 28 days
|
|
Frequency and severity of adverse drug reactions (ADRs) and serious adverse events (SAEs)
Ramy czasowe: During 1st cycle with REKOVELLE (each cycle range is 5-20 days, average 9 days), Up to 10-11 weeks after transfer
|
Frequency and severity of ADRs and SAEs as defined by the investigator |
During 1st cycle with REKOVELLE (each cycle range is 5-20 days, average 9 days), Up to 10-11 weeks after transfer
|
|
Preventive interventions for ovarian hyperstimulation syndrome (OHSS)
Ramy czasowe: During 1st cycle with REKOVELLE (each cycle range is 5-20 days, average 9 days), Up to 10-11 weeks after transfer.
|
Preventive interventions decided by the investigator (Triggering of final follicular maturation with GnRH agonist and fresh embryo/blastocyst transfer or cryopreservation, Cancellation of fresh embryo/blastocyst transfer) |
During 1st cycle with REKOVELLE (each cycle range is 5-20 days, average 9 days), Up to 10-11 weeks after transfer.
|
|
Number of subjects with mild / moderate / severe ovarian hyperstimulation syndrome (OHSS)
Ramy czasowe: During 1st cycle with REKOVELLE (each cycle range is 5-20 days, average 9 days), Up to 10-11 weeks after transfer
|
Number of subjects with mild / moderate / severe OHSS, defined by the investigator |
During 1st cycle with REKOVELLE (each cycle range is 5-20 days, average 9 days), Up to 10-11 weeks after transfer
|
Współpracownicy i badacze
Sponsor
Sponsor
Śledczy
Śledczy
- Dyrektor Studium: Global Clinical Compliance, Ferring Pharmaceuticals
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów (Rzeczywisty)
Rozpoczęcie studiów
Zakończenie podstawowe (Szacowany)
Zakończenie podstawowe
Ukończenie studiów (Szacowany)
Ukończenie studiów
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Rzeczywisty)
Pierwszy wysłany
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
Ostatnia wysłana aktualizacja
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Dodatkowe istotne warunki MeSH
Inne numery identyfikacyjne badania
Inne numery identyfikacyjne badania
- 000430
Plan dla danych uczestnika indywidualnego (IPD)
Planujesz udostępniać dane poszczególnych uczestników (IPD)?
Informacje o lekach i urządzeniach, dokumenty badawcze
Bada produkt leczniczy regulowany przez amerykańską FDA
Bada produkt urządzenia regulowany przez amerykańską FDA
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .